vs
ADMA BIOLOGICS, INC.（ADMA）与AerSale Corp（ASLE）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是AerSale Corp的1.5倍（$139.2M vs $90.9M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 5.9%，领先29.5%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -4.0%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $9.8M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 0.2%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
ADMA vs ASLE — 直观对比
营收规模更大
ADMA
是对方的1.5倍
$90.9M
营收增速更快
ADMA
高出22.4%
-4.0%
净利率更高
ADMA
高出29.5%
5.9%
自由现金流更多
ADMA
多$24.8M
$9.8M
两年增速更快
ADMA
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $90.9M |
| 净利润 | $49.4M | $5.4M |
| 毛利率 | 63.8% | 34.1% |
| 营业利润率 | 45.1% | 7.8% |
| 净利率 | 35.5% | 5.9% |
| 营收同比 | 18.4% | -4.0% |
| 净利润同比 | -55.9% | 99.7% |
| 每股收益（稀释后） | $0.20 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAASLE
| Q4 25 | $139.2M | $90.9M | ||
| Q3 25 | $134.2M | $71.2M | ||
| Q2 25 | $122.0M | $107.4M | ||
| Q1 25 | $114.8M | $65.8M | ||
| Q4 24 | $117.5M | $94.7M | ||
| Q3 24 | $119.8M | $82.7M | ||
| Q2 24 | $107.2M | $77.1M | ||
| Q1 24 | $81.9M | $90.5M |
净利润ADMAASLE
| Q4 25 | $49.4M | $5.4M | ||
| Q3 25 | $36.4M | $-120.0K | ||
| Q2 25 | $34.2M | $8.6M | ||
| Q1 25 | $26.9M | $-5.3M | ||
| Q4 24 | $111.9M | $2.7M | ||
| Q3 24 | $35.9M | $509.0K | ||
| Q2 24 | $32.1M | $-3.6M | ||
| Q1 24 | $17.8M | $6.3M |
毛利率ADMAASLE
| Q4 25 | 63.8% | 34.1% | ||
| Q3 25 | 56.3% | 30.2% | ||
| Q2 25 | 55.1% | 32.9% | ||
| Q1 25 | 53.2% | 27.3% | ||
| Q4 24 | 53.9% | 31.4% | ||
| Q3 24 | 49.8% | 28.6% | ||
| Q2 24 | 53.6% | 28.2% | ||
| Q1 24 | 47.8% | 31.8% |
营业利润率ADMAASLE
| Q4 25 | 45.1% | 7.8% | ||
| Q3 25 | 38.0% | 4.0% | ||
| Q2 25 | 35.1% | 11.7% | ||
| Q1 25 | 30.4% | -10.1% | ||
| Q4 24 | 32.6% | 5.2% | ||
| Q3 24 | 33.1% | 2.4% | ||
| Q2 24 | 36.6% | -2.4% | ||
| Q1 24 | 26.7% | 5.2% |
净利率ADMAASLE
| Q4 25 | 35.5% | 5.9% | ||
| Q3 25 | 27.1% | -0.2% | ||
| Q2 25 | 28.1% | 8.0% | ||
| Q1 25 | 23.4% | -8.0% | ||
| Q4 24 | 95.2% | 2.9% | ||
| Q3 24 | 30.0% | 0.6% | ||
| Q2 24 | 29.9% | -4.7% | ||
| Q1 24 | 21.7% | 6.9% |
每股收益（稀释后）ADMAASLE
| Q4 25 | $0.20 | $0.10 | ||
| Q3 25 | $0.15 | $0.00 | ||
| Q2 25 | $0.14 | $0.18 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.45 | $0.05 | ||
| Q3 24 | $0.15 | $0.01 | ||
| Q2 24 | $0.13 | $-0.07 | ||
| Q1 24 | $0.08 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $4.4M |
| 总债务越低越好 | $72.1M | $1.3M |
| 股东权益账面价值 | $477.3M | $424.4M |
| 总资产 | $624.2M | $640.5M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资ADMAASLE
| Q4 25 | $87.6M | $4.4M | ||
| Q3 25 | $61.4M | $5.3M | ||
| Q2 25 | $90.3M | $5.7M | ||
| Q1 25 | $71.6M | $4.7M | ||
| Q4 24 | $103.1M | $4.7M | ||
| Q3 24 | $86.7M | $9.8M | ||
| Q2 24 | $88.2M | $4.3M | ||
| Q1 24 | $45.3M | $2.6M |
总债务ADMAASLE
| Q4 25 | $72.1M | $1.3M | ||
| Q3 25 | $72.4M | $1.5M | ||
| Q2 25 | — | $907.0K | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | $72.3M | $1.2M | ||
| Q3 24 | — | $376.0K | ||
| Q2 24 | — | $522.0K | ||
| Q1 24 | — | $3.5M |
股东权益ADMAASLE
| Q4 25 | $477.3M | $424.4M | ||
| Q3 25 | $431.2M | $417.1M | ||
| Q2 25 | $398.3M | $415.9M | ||
| Q1 25 | $373.4M | $406.5M | ||
| Q4 24 | $349.0M | $455.6M | ||
| Q3 24 | $231.9M | $451.5M | ||
| Q2 24 | $188.3M | $449.8M | ||
| Q1 24 | $153.7M | $452.0M |
总资产ADMAASLE
| Q4 25 | $624.2M | $640.5M | ||
| Q3 25 | $568.7M | $646.3M | ||
| Q2 25 | $558.4M | $646.7M | ||
| Q1 25 | $510.6M | $646.1M | ||
| Q4 24 | $488.7M | $604.7M | ||
| Q3 24 | $390.6M | $601.5M | ||
| Q2 24 | $376.4M | $598.7M | ||
| Q1 24 | $350.9M | $571.7M |
负债/权益比ADMAASLE
| Q4 25 | 0.15× | 0.00× | ||
| Q3 25 | 0.17× | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | 0.21× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.01× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $11.4M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $9.8M |
| 自由现金流率自由现金流/营收 | 24.8% | 10.8% |
| 资本支出强度资本支出/营收 | 0.8% | 1.7% |
| 现金转化率经营现金流/净利润 | 0.72× | 2.11× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $-29.1M |
8季度趋势，按日历期对齐
经营现金流ADMAASLE
| Q4 25 | $35.6M | $11.4M | ||
| Q3 25 | $13.3M | $-8.9M | ||
| Q2 25 | $21.1M | $19.8M | ||
| Q1 25 | $-19.7M | $-45.2M | ||
| Q4 24 | $50.2M | $37.5M | ||
| Q3 24 | $25.0M | $10.4M | ||
| Q2 24 | $45.6M | $-15.3M | ||
| Q1 24 | $-2.2M | $-21.5M |
自由现金流ADMAASLE
| Q4 25 | $34.6M | $9.8M | ||
| Q3 25 | $-1.1M | $-9.8M | ||
| Q2 25 | $18.7M | $18.6M | ||
| Q1 25 | $-24.4M | $-47.6M | ||
| Q4 24 | $47.5M | $32.3M | ||
| Q3 24 | $24.0M | $8.9M | ||
| Q2 24 | $43.6M | $-18.9M | ||
| Q1 24 | $-4.6M | $-25.0M |
自由现金流率ADMAASLE
| Q4 25 | 24.8% | 10.8% | ||
| Q3 25 | -0.8% | -13.8% | ||
| Q2 25 | 15.3% | 17.3% | ||
| Q1 25 | -21.2% | -72.4% | ||
| Q4 24 | 40.4% | 34.0% | ||
| Q3 24 | 20.0% | 10.7% | ||
| Q2 24 | 40.7% | -24.6% | ||
| Q1 24 | -5.6% | -27.7% |
资本支出强度ADMAASLE
| Q4 25 | 0.8% | 1.7% | ||
| Q3 25 | 10.7% | 1.3% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 3.7% | ||
| Q4 24 | 2.3% | 5.6% | ||
| Q3 24 | 0.9% | 1.9% | ||
| Q2 24 | 1.9% | 4.7% | ||
| Q1 24 | 2.9% | 3.9% |
现金转化率ADMAASLE
| Q4 25 | 0.72× | 2.11× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | 2.31× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 13.89× | ||
| Q3 24 | 0.70× | 20.52× | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | -3.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
